Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Conditions
Interventions
ASN001: Escalating dose Part A
Locations
6
United States
UCLA Medical Center, Clark Urology Center
Los Angeles, California, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
Philadelphia, Pennsylvania, United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Start Date
January 19, 2015
Primary Completion Date
July 14, 2017
Completion Date
August 17, 2017
Last Updated
March 7, 2018
NCT06844383
NCT06926283
NCT06594926
NCT07177937
NCT06487507
NCT05919264
Lead Sponsor
Asana BioSciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions